Table of Content

1 Product Definition

2 Scope of Research
2.1 Scope of Study
2.2 Inclusion and Exclusion Criteria
2.2.1 Inclusion Criteria
2.2.2 Exclusion Criteria
2.3 Key Questions Answered in the Report

3 Research Methodology
3.1 Data Collection and Analysis
3.2 Data Sources
3.2.1 Primary Data Sources
3.2.2 Secondary Data Sources
3.3 Data Triangulation
3.4 Market Estimation
3.5 Forecast Period Selection Criteria
3.6 Assumptions and Limitations

4 Impact of COVID-19 on Ophthalmic Drug Delivery Devices
4.1 Impact on Treatment Facilities
4.2 Impact on Market Size
4.2.1 Scenario Comparative Analysis (Pre-COVID-19, During COVID-19, Post-COVID-19)
4.3 Future Outlook and Recommendations

5 Industry Analysis
5.1 Technology and Innovation Landscape
5.1.1 Key Trends
5.1.1.1 Short-Term Impact
5.1.1.2 Mid-Term Impact
5.1.1.3 Long-Term Impact
5.1.1.4 Future Outlook
5.2 Epidemiological Landscape
5.2.1 Glaucoma
5.2.2 Age-Related Macular Degeneration
5.2.3 Cataract
5.3 Value Chain Analysis
5.4 End User Perceptions
5.5 Regulatory Framework
5.5.1 Regulatory Framework in North America
5.5.1.1 Key Takeaways
5.5.2 Regulatory Framework in Europe
5.5.2.1 Key Takeaways
5.5.3 Regulatory Framework in Asia-Pacific
5.5.3.1 Key Takeaways
5.6 Patent Analysis
5.6.1 Patent Filed, by Year
5.6.2 Patent Filed, by Country/Cluster
5.7 Product Benchmarking

6 Competitive Landscape
6.1 Market Share Analysis
6.2 Key Strategies and Developments
6.2.1 Regulatory and Legal Activities
6.2.2 Partnerships, Alliances, and Business Expansions
6.2.3 New Offerings
6.2.4 Funding Activities
6.2.5 Mergers and Acquisitions
6.3 Business Model Analysis
6.4 Key Players-Competitive Benchmarking

7 Global Ophthalmic Drug Delivery Devices Market Scenario
7.1 Assumptions and Limitations
7.2 Key Findings and Opportunity Assessment
7.2.1 Key Findings
7.2.2 Opportunity Assessment
7.3 Global Ophthalmic Drug Delivery Devices Market Size and Forecast
7.3.1 Realistic Growth Scenario
7.3.2 Pessimistic/Conservative Growth Scenario
7.3.3 Optimistic Scenario
7.4 Market Dynamics
7.4.1 Impact Analysis
7.4.2 Market Growth Promoting Factors
7.4.2.1 Increasing Prevalence of Ocular Disorders
7.4.2.2 Development of Novel Drug Dispensers
7.4.2.3 Integration of Digital Solutions in Ophthalmic Drug Delivery Devices
7.4.2.4 Regular Funding Cycles for Emerging Companies
7.4.3 Market Growth Restraining Factors
7.4.3.1 High Upfront Cost of Advanced Ophthalmic Drug Delivery Devices
7.4.3.2 Prolonged Regulatory Approval Process
7.4.4 Market Opportunities
7.4.4.1 Entry of Regional Companies in Global Ophthalmic Drug Delivery Devices Market
7.4.4.2 Partnerships between Companies and Ophthalmic Clinics
7.4.4.3 Inclusion of Nanotechnology in Ophthalmic Drugs Formulation
7.4.4.4 Opportunities Potential
7.4.4.4.1 Short-Term
7.4.4.4.2 Mid-Term
7.4.4.4.3 Long-Term

8 Global Ophthalmic Drug Delivery Devices Market (by Product), 2018-2030
8.1 Growth Share Matrix
8.2 Pre-Filled Syringes
8.3 Multidose Eyedroppers
8.4 Squeeze Dispenser
8.5 Mist Sprayers
8.6 Add-On Devices
8.7 Contact Lenses
8.8 Others (Tubes, Ocular Inserts)

9 Global Ophthalmic Drug Delivery Devices Market (by Formulation), 2018-2030
9.1 Growth Share Matrix
9.2 Eye Drops
9.3 Liquid Sprays
9.4 Ointments
9.5 Gels
9.6 Others (Emulsions, Suspensions, Etc.)

10 Global Ophthalmic Drug Delivery Devices Market (by Sales Channel), 2018-2030
10.1 Opportunity Assessment
10.2 Growth Share Matrix
10.3 Direct Sales
10.4 Indirect Sales

11 Global Ophthalmic Drug Delivery Devices Market (by End User), 2018-2030
11.1 Opportunity Assessment
11.2 Hospitals
11.3 Clinics
11.4 Homecare Settings
11.5 Others (Standalone, Specialty Centers)

12 Global Ophthalmic Drug Delivery Devices Market (by Region), 2018-2030
12.1 Overview
12.2 North America Ophthalmic Drug Delivery Devices Market
12.2.1 Key Findings and Opportunity Assessment
12.2.2 Market Dynamics: Impact Analysis
12.2.3 Market Size and Forecast
12.2.3.1 by Sales Channel
12.2.3.2 by End User
12.2.3.3 by Country
12.2.3.3.1 U.S.
12.2.3.3.2 Canada
12.3 Europe Ophthalmic Drug Delivery Devices Market
12.3.1 Key Findings and Opportunity Assessment
12.3.2 Market Dynamics: Impact Analysis
12.3.3 Market Size and Forecast
12.3.3.1 by Sales Channel
12.3.3.2 by End User
12.3.3.3 by Country
12.3.3.3.1 Germany
12.3.3.3.2 U.K.
12.3.3.3.3 France
12.3.3.3.4 Italy
12.3.3.3.5 Spain
12.3.3.3.6 Nordic Countries
12.3.3.3.7 Rest-of-Europe
12.4 Asia-Pacific Ophthalmic Drug Delivery Devices Market
12.4.1 Key Findings and Opportunity Assessment
12.4.2 Market Dynamics: Impact Analysis
12.4.3 Market Size and Forecast
12.4.3.1 by Sales Channel
12.4.3.2 by End User
12.4.3.3 by Country
12.4.3.3.1 Japan
12.4.3.3.2 China
12.4.3.3.3 India
12.4.3.3.4 South Korea
12.4.3.3.5 Australia and New Zealand
12.4.3.3.6 Singapore
12.4.3.3.7 Rest-of-Asia-Pacific
12.5 Latin America Ophthalmic Drug Delivery Devices Market
12.5.1 Key Findings and Opportunity Assessment
12.5.2 Market Dynamics: Impact Analysis
12.5.3 Market Size and Forecast
12.5.3.1 by Sales Channel
12.5.3.2 by End User
12.5.3.3 by Country
12.5.3.3.1 Brazil
12.5.3.3.2 Mexico
12.5.3.3.3 Argentina
12.5.3.3.4 Colombia
12.5.3.3.5 Rest-of-Latin America
12.6 Middle East and Africa Ophthalmic Drug Delivery Devices Market
12.6.1 Key Findings and Opportunity Assessment
12.6.2 Market Dynamics: Impact Analysis
12.6.3 Market Size and Forecast
12.6.3.1 by Sales Channel
12.6.3.2 by End User
12.6.3.3 by Country
12.6.3.3.1 K.S.A.
12.6.3.3.2 Israel
12.6.3.3.3 South Africa
12.6.3.3.4 Rest-of-Middle East and Africa

13 Company Profiles
13.1 Overview
13.2 Established Companies
13.2.1 Aero Pump GmbH
13.2.1.1 Company Overview
13.2.1.2 Role of Aero Pump GmbH in Global Ophthalmic Drug Delivery Devices Market
13.2.1.3 SWOT Analysis
13.2.2 AptarGroup, Inc.
13.2.2.1 Company Overview
13.2.2.2 Role of AptarGroup, Inc. in Global Ophthalmic Drug Delivery Devices Market
13.2.2.3 Financials
13.2.2.4 R&D Insights
13.2.2.5 Recent Developments
13.2.2.6 SWOT Analysis
13.2.3 Bausch Health Companies Inc.
13.2.3.1 Company Overview
13.2.3.2 Role of Bausch Health Companies Inc. in Global Ophthalmic Drug Delivery Devices Market
13.2.3.3 Financials
13.2.3.4 R&D Insights
13.2.3.5 Recent Developments
13.2.3.6 SWOT Analysis
13.2.4 Becton, Dickinson and Company
13.2.4.1 Company Overview
13.2.4.2 Role of Becton, Dickinson and Company in the Global Ophthalmic Drug Delivery Devices Market
13.2.4.3 Financials
13.2.4.4 R&D Insights
13.2.4.5 Recent Developments
13.2.4.6 SWOT Analysis
13.2.5 EyePoint Pharmaceuticals, Inc.
13.2.5.1 Company Overview
13.2.5.2 Role of EyePoint Pharmaceuticals, Inc. in Global Ophthalmic Drug Delivery Devices Market
13.2.5.3 Financials
13.2.5.4 R&D Insights
13.2.5.5 Recent Developments
13.2.5.6 SWOT Analysis
13.2.6 Gaplast GmbH
13.2.6.1 Company Overview
13.2.6.2 Role of Gaplast GmbH in Global Ophthalmic Drug Delivery Devices Market
13.2.6.3 Recent Developments
13.2.6.4 SWOT Analysis
13.2.7 Gerresheimer AG
13.2.7.1 Company Overview
13.2.7.2 Role of Gerresheimer AG in Global Ophthalmic Drug Delivery Devices Market
13.2.7.3 Financials
13.2.7.4 R&D Insights
13.2.7.5 Recent Developments
13.2.7.6 SWOT Analysis
13.2.8 Jotteq Inc.
13.2.8.1 Company Overview
13.2.8.2 Role of Jotteq Inc. in Global Ophthalmic Drug Delivery Devices Market
13.2.8.3 SWOT Analysis
13.2.9 Nemera
13.2.9.1 Company Overview
13.2.9.2 Role of Nemera in Global Ophthalmic Drug Delivery Devices Market
13.2.9.3 Recent Developments
13.2.9.4 SWOT Analysis
13.2.10 Nipro Corporation
13.2.10.1 Company Overview
13.2.10.2 Role of Nipro Corporation in Global Ophthalmic Drug Delivery Devices Market
13.2.10.3 Financials
13.2.10.4 R&D Insights
13.2.10.5 Recent Developments
13.2.10.6 SWOT Analysis
13.2.11 Ocular Therapeutix, Inc.
13.2.11.1 Company Overview
13.2.11.2 Role of Ocular Therapeutix, Inc. in Global Ophthalmic Drug Delivery Devices Market
13.2.11.3 Financials
13.2.11.4 R&D Insights
13.2.11.5 Recent Developments
13.2.11.6 SWOT Analysis
13.2.12 Owen Mumford
13.2.12.1 Company Overview
13.2.12.2 Role of Owen Mumford in the Global Ophthalmic Drug Delivery Devices Market
13.2.12.3 SWOT Analysis
13.2.13 Silgan Holdings Inc.
13.2.13.1 Company Overview
13.2.13.2 Role of Silgan Holdings Inc. in Global Ophthalmic Drug Delivery Devices Market
13.2.13.3 Financials
13.2.13.4 SWOT Analysis
13.2.14 Terumo Corporation
13.2.14.1 Company Overview
13.2.14.2 Role of Terumo Corporation in Global Ophthalmic Drug Delivery Devices Market
13.2.14.3 Financials
13.2.14.4 R&D Insights
13.2.14.5 Recent Developments
13.2.14.6 SWOT Analysis
13.2.15 West Pharmaceutical Services, Inc.
13.2.15.1 Company Overview
13.2.15.2 Role of West Pharmaceutical Services, Inc. in the Global Ophthalmic Drug Delivery Devices Market
13.2.15.3 Financials
13.2.15.4 R&D Insights
13.2.15.5 SWOT Analysis
13.3 Company Snapshots
13.3.1 Kedalion Therapeutics, Inc.
13.3.1.1 Company Overview
13.3.1.2 Role of Kedalion Therapeutics, Inc. in Global Ophthalmic Drug Delivery Devices Market
13.3.1.3 Recent Developments
13.3.2 Re-Vana Therapeutics
13.3.2.1 Company Overview
13.3.2.2 Role of Re-Vana Therapeutics in Global Ophthalmic Drug Delivery Devices Market
13.3.2.3 Recent Developments
13.3.3 Mati Therapeutics, Inc.
13.3.3.1 Company Overview
13.3.3.2 Role of Mati Therapeutics, Inc. in Global Ophthalmic Drug Delivery Devices Market
13.3.4 Biocorp
13.3.4.1 Company Overview
13.3.4.2 Role of Biocorp in Global Ophthalmic Drug Delivery Devices Market
13.3.4.3 Recent Developments
13.3.5 Ocumedic, Inc.
13.3.5.1 Company Overview
13.3.5.2 Role of Ocumedic, Inc. in Global Ophthalmic Drug Delivery Devices Market
13.3.5.3 Recent Developments
List of Tables
Table 1: Global Estimates of Common Ocular Conditions
Table 2: Global Ophthalmic Drug Delivery Devices Market, Quarterly Regional Impact, 2020
Table 2.1: Global Ophthalmic Drug Delivery Devices Market, Exclusion Criteria
Table 4.1: Pre-COVID-19 Patient Volume in Private Ophthalmology Practices, July 2020
Table 5.1: Regulatory Framework in North America
Table 5.2: Regulatory Framework in Europe
Table 5.3: Regulatory Framework in Asia-Pacific
Table 5.4: Global Ophthalmic Drug Delivery Devices Market: Product Benchmarking
Table 6.1: Global Ophthalmic Drug Delivery Devices Market, Business Model Analysis
Table 7.1: Global Ophthalmic Drug Delivery Devices Market, Funding Cycles
Table 12.1: Prevalence of Ocular Disorders in North America, 2016, 2019, and 2030
Table 12.2: North America Ophthalmic Drug Delivery Devices Market, Impact Analysis
Table 12.3: Prevalence of Ocular Disorders in the U.S., 2000, 2010, and 2019
Table 12.4: Prevalence of Ocular Disorders in Canada, 2000, 2010, and 2019
Table 12.5: Prevalence of Ocular Disorders in Europe, 2016, 2019, and 2030
Table 12.6: Europe Ophthalmic Drug Delivery Devices Market, Impact Analysis
Table 12.7: Prevalence of Ocular Disorders in Germany, 2000, 2010, and 2019
Table 12.8: Prevalence of Ocular Disorders in the U.K., 2000, 2010, and 2019
Table 12.9: Prevalence of Ocular Disorders in France, 2000, 2010, and 2019
Table 12.10: Prevalence of Ocular Disorders in Italy, 2000, 2010, and 2019
Table 12.11: Prevalence of Ocular Disorders in Spain, 2000, 2010, and 2019
Table 12.12: Prevalence of Ocular Disorders in Nordic Countries, 2000, 2010, and 2019
Table 12.13: Prevalence of Ocular Disorders in Asia-Pacific, 2016, 2019, and 2030
Table 12.14: Asia-Pacific Ophthalmic Drug Delivery Devices Market, Impact Analysis
Table 12.15: Prevalence of Ocular Disorders in Japan, 2000, 2010, and 2019
Table 12.16: Prevalence of Ocular Disorders in China, 2000, 2010, and 2019
Table 12.17: Prevalence of Ocular Disorders in India, 2000, 2010, and 2019
Table 12.18: Prevalence of Ocular Disorders in South Korea, 2000, 2010, and 2019
Table 12.19: Prevalence of Ocular Disorders in Australia and New Zealand, 2000, 2010, and 2019
Table 12.20: Prevalence of Ocular Disorders in Singapore, 2000, 2010, and 2019
Table 12.21: Prevalence of Ocular Disorders in Latin America, 2016, 2019, and 2030
Table 12.22: Latin America Ophthalmic Drug Delivery Devices Market, Impact Analysis
Table 12.23: Prevalence of Ocular Disorders in Brazil, 2000, 2010, and 2019
Table 12.24: Prevalence of Ocular Disorders in Mexico, 2000, 2010, and 2019
Table 12.25: Prevalence of Ocular Disorders in Argentina, 2000, 2010, and 2019
Table12.26: Prevalence of Ocular Disorders in Colombia, 2000, 2010, and 2019
Table 12.27: Prevalence of Ocular Disorders in Middle East and Africa, 2016, 2019, and 2030
Table 12.28: Middle East and Africa Ophthalmic Drug Delivery Devices Market, Impact Analysis
Table 12.29: Prevalence of Ocular Disorders in the K.S.A., 2000, 2010, and 2019
Table 12.30: Prevalence of Ocular Disorders in Israel, 2000, 2010, and 2019
Table 12.31: Prevalence of Ocular Disorders in South Africa, 2000, 2010, and 2019
List of Figures
Figure 1: Global Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 2: Global Ophthalmic Drug Delivery Devices Market, Impact Analysis
Figure 3: Global Ophthalmic Drug Delivery Devices Market, Companies Benchmarking
Figure 4: Global Ophthalmic Drug Delivery Devices Market (by End User), 2018 and 2030
Figure 5: Global Ophthalmic Drug Delivery Devices Market (by Region), 2018 and 2030
Figure 2.1: Global Ophthalmic Drug Delivery Devices Market Segmentation
Figure 3.1: Global Ophthalmic Drug Delivery Devices Market: Research Methodology
Figure 3.2: Primary Research
Figure 3.3: Secondary Research
Figure 3.4: Data Triangulation
Figure 3.5: Assumptions and Limitations
Figure 4.1: Global Ophthalmic Drug Delivery Devices Market, Scenario Comparative Analysis
Figure 5.1: Global Ophthalmic Drug Delivery Devices Market: Key Trends
Figure 5.2: Global Ophthalmic Drug Delivery Devices Market, Short-Term Impact of Key Trends
Figure 5.3: Global Ophthalmic Drug Delivery Devices Market, Mid-Term Impact of Key Trends
Figure 5.4: Global Ophthalmic Drug Delivery Devices Market, Long-Term Impact of Key Trends
Figure 5.5: Global Prevalence, Glaucoma, 2016-2030
Figure 5.6: Glaucoma Prevalence, by Region, 2016-2030
Figure 5.7: Global Prevalence, Age-Related Macular Degeneration, 2016-2030
Figure 5.8: Age-Related Macular Degeneration Prevalence, by Region, 2016-2030
Figure 5.9: Global Prevalence, Cataract, 2016-2030
Figure 5.10: Cataract Prevalence, by Region, 2016-2030
Figure 5.11: Global Ophthalmic Drug Delivery Devices Market: Value Chain Analysis
Figure 5.12: Global Ophthalmic Drug Delivery Devices Market: End User Perception
Figure 5.13: Global Ophthalmic Drug Delivery Devices Market, Patent Filing Trend, January 2016-July 2021
Figure 5.14: Global Ophthalmic Drug Delivery Devices Market, Patent Filing Trend (by Country)
Figure 6.1: Global Ophthalmic Drug Delivery Devices Market Share Analysis (by Company), 2020
Figure 6.2: Share of Key Developments and Strategies in the Global Ophthalmic Drug Delivery Devices Market (by Category), January 2018-June 2021
Figure 6.3: Regulatory and Legal Activities (by Company), January 2018-June 2021
Figure 6.4: Partnerships, Alliances, and Business Expansions (by Company), January 2018-June 2021
Figure 6.5: New Offerings (by Company), January 2018-June 2021
Figure 6.6: Funding Activities (by Company), January 2018-June 2021
Figure 6.7: Mergers and Acquisitions (by Company), January 2018-June 2021
Figure 6.8: Global Ophthalmic Drug Delivery Devices Market, Growth Share Matrix (by Product), 2018-2030
Figure 7.1: Global Ophthalmic Drug Delivery Devices Market, Realistic Growth Scenario, $Million, 2018-2030
Figure 7.2: Global Ophthalmic Drug Delivery Devices Market, Pessimistic/Conservative Growth Scenario, $Million, 2018-2030
Figure 7.3: Global Ophthalmic Drug Delivery Devices Market, Optimistic Growth Scenario, $Million, 2018-2030
Figure 7.4: Global Ophthalmic Drug Delivery Devices Market, Impact Analysis
Figure 7.5: Increasing Prevalence of Ocular Disorders, 2016-2019
Figure 8.1: Global Ophthalmic Drug Delivery Devices Market, Incremental Opportunity, (by Product), $Million, 2018 and 2030
Figure 8.2: Global Ophthalmic Drug Delivery Devices Market (by Product), Growth Share Matrix
Figure 8.3: Global Ophthalmic Drug Delivery Devices Market (Pre-Filled Syringes), $Million, 2018-2030
Figure 8.4: Global Ophthalmic Drug Delivery Devices Market (Multidose Eyedroppers), $Million, 2018-2030
Figure 8.5: Global Ophthalmic Drug Delivery Devices Market (Squeeze Dispenser), $Million, 2018-2030
Figure 8.6: Global Ophthalmic Drug Delivery Devices Market (Mist Sprayers), $Million, 2018-2030
Figure 8.7: Global Ophthalmic Drug Delivery Devices Market (Add-On Devices), $Million, 2018-2030
Figure 8.8: Global Ophthalmic Drug Delivery Devices Market (Contact Lenses), $Million, 2018-2030
Figure 8.9: Global Ophthalmic Drug Delivery Devices Market (Others), $Million, 2018-2030
Figure 9.1: Global Ophthalmic Drug Delivery Devices Market, Incremental Opportunity, (by Formulation), $Million, 2018 and 2030
Figure 9.2: Global Ophthalmic Drug Delivery Devices Market (by Formulation), Growth Share Matrix
Figure 9.3: Global Ophthalmic Drug Delivery Devices Market (Eye Drops), $Million, 2018-2030
Figure 9.4: Global Ophthalmic Drug Delivery Devices Market (Liquid Sprays), $Million, 2018-2030
Figure 9.5: Global Ophthalmic Drug Delivery Devices Market (Ointments), $Million, 2018-2030
Figure 9.6: Global Ophthalmic Drug Delivery Devices Market (Gels), $Million, 2018-2030
Figure 9.7: Global Ophthalmic Drug Delivery Devices Market (Others), $Million, 2018-2030
Figure 10.1: Global Ophthalmic Drug Delivery Devices Market, Incremental Opportunity, (by Sales Channel), $Million, 2018 and 2030
Figure 10.2: Global Ophthalmic Drug Delivery Devices Market (by Sales Channel), Growth Share Matrix
Figure 10.3: Global Ophthalmic Drug Delivery Devices Market (Direct Sales), $Million, 2018-2030
Figure 10.4: Global Ophthalmic Drug Delivery Devices Market (Indirect Sales), $Million, 2018-2030
Figure 11.1: Global Ophthalmic Drug Delivery Devices Market (by End User), Incremental Opportunity, (by End User), $Million, 2018 and 2030
Figure 11.2: Global Ophthalmic Drug Delivery Devices Market (Hospitals), $Million, 2018-2030
Figure 11.3: Global Ophthalmic Drug Delivery Devices Market (Clinics), $Million, 2018-2030
Figure 11.4: Global Ophthalmic Drug Delivery Devices Market (Homecare Settings), $Million, 2018-2030
Figure 11.5: Global Ophthalmic Drug Delivery Devices Market (Others), $Million, 2018-2030
Figure 12.1: Global Ophthalmic Drug Delivery Devices Market, (by Region), 2018 and 2030
Figure 12.2: North America Ophthalmic Drug Delivery Devices Market, Incremental Growth Opportunity, $Million, 2018 and 2030
Figure 12.3: North America Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.4: North America Ophthalmic Drug Delivery Devices Market, (by Sales Channel), $Million, 2018-2030
Figure 12.5: North America Ophthalmic Drug Delivery Devices Market, (by End User), $Million, 2018-2030
Figure 12.6: North America Ophthalmic Drug Delivery Devices Market (by Country)
Figure 12.7: U.S. Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.8: Canada Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.9: Europe Ophthalmic Drug Delivery Devices Market, Incremental Growth Opportunity, $Million, 2018 and 2030
Figure 12.10: Europe Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.11: Europe Ophthalmic Drug Delivery Devices Market, (by Sales Channel), $Million, 2018-2030
Figure 12.12: Europe Ophthalmic Drug Delivery Devices Market, (by End User), $Million, 2018-2030
Figure 12.13: Europe Ophthalmic Drug Delivery Devices Market (by Country)
Figure 12.14: Germany Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.15: U.K. Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.16: France Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.17: Italy Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.18: Spain Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.19: Nordic Countries Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.20: Rest-of-Europe Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.21: Asia-Pacific Ophthalmic Drug Delivery Devices Market, Incremental Growth Opportunity, $Million, 2018 and 2030
Figure 12.22: Asia-Pacific Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.23: Asia-Pacific Ophthalmic Drug Delivery Devices Market, (by Sales Channel), $Million, 2018-2030
Figure 12.24: Asia-Pacific Ophthalmic Drug Delivery Devices Market, (by End User), $Million, 2018-2030
Figure 12.25: Asia-Pacific Ophthalmic Drug Delivery Devices Market (by Country)
Figure 12.26: Japan Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.27: China Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.28: India Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.29: South Korea Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.30: Australia and New Zealand Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.31: Singapore Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.32: Rest-of-Asia-Pacific Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.33: Latin America Ophthalmic Drug Delivery Devices Market, Incremental Growth Opportunity, $Million, 2018 and 2030
Figure 12.34: Latin America Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.35: Latin America Ophthalmic Drug Delivery Devices Market, (by Sales Channel), $Million, 2018-2030
Figure 12.36: Latin America Ophthalmic Drug Delivery Devices Market, (by End User), $Million, 2018-2030
Figure 12.37: Latin America Ophthalmic Drug Delivery Devices Market (by Country)
Figure 12.38: Brazil Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.39: Mexico Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.40: Argentina Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.41: Colombia Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.42: Rest-of-Latin America Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.43: Middle East and Africa Ophthalmic Drug Delivery Devices Market, Incremental Growth Opportunity, $Million, 2018 and 2030
Figure 12.44: Middle East and Africa Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.45: Middle East and Africa Ophthalmic Drug Delivery Devices Market, (by Sales Channel), $Million, 2018-2030
Figure 12.46: Middle East and Africa Ophthalmic Drug Delivery Devices Market, (by End User), $Million, 2018-2030
Figure 12.47: Middle East and Africa Ophthalmic Drug Delivery Devices Market (by Country)
Figure 12.48: K.S.A. Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.49: Israel Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.50: South Africa Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 12.51: Rest-of-Middle East and Africa Ophthalmic Drug Delivery Devices Market, $Million, 2018-2030
Figure 13.1: Shares of Key Companies Profiled
Figure 13.2: Aero Pump GmbH: Overall Product Portfolio
Figure 13.3: Aero Pump GmbH: SWOT Analysis
Figure 13.4: AptarGroup, Inc.: Overall Product Portfolio
Figure 13.5: AptarGroup, Inc.: Overall Financials, 2018-2020
Figure 13.6: AptarGroup, Inc.: Net Revenue (by Segment), $Million, 2018-2020
Figure 13.7: AptarGroup, Inc.: Net Revenue (by Region), $Million, 2018-2020
Figure 13.8: AptarGroup, Inc.: R&D Expenditure, 2018-2020
Figure 13.9: AptarGroup, Inc: SWOT Analysis
Figure 13.10: Bausch Health Companies Inc.: Overall Product Portfolio
Figure 13.11: Bausch Health Companies Inc.: Overall Financials, 2018-2020
Figure 13.12: Bausch Health Companies Inc.: Revenue (by Segment), 2018-2020
Figure 13.13: Bausch Health Companies Inc.: Revenue (by Region), 2018-2020
Figure 13.14: Bausch Health Companies Inc.: R&D Expense, 2018-2020
Figure 13.15: Bausch Health Companies Inc.: SWOT Analysis
Figure 13.16: Becton, Dickinson and Company: Overall Product Portfolio
Figure 13.17: Becton, Dickinson and Company: Overall Financials, 2018-2020
Figure 13.18: Becton, Dickinson and Company: Net Revenue (by Segment), $Million, 2018-2020
Figure 13.19: Becton, Dickinson and Company: Net Revenue (by Region), $Million, 2018-2020
Figure 13.20: Becton, Dickinson and Company: R&D Expenditure, 2018-2020
Figure 13.21: Becton, Dickinson and Company: SWOT Analysis
Figure 13.22: EyePoint Pharmaceuticals, Inc.: Overall Product Portfolio
Figure 13.23: EyePoint Pharmaceuticals, Inc.: Overall Financials, 2018-2020
Figure 13.24: EyePoint Pharmaceuticals, Inc.: Revenue (by Region), 2018-2020
Figure 13.25: EyePoint Pharmaceuticals, Inc.: R&D Expenditure, 2018-2020
Figure 13.26: EyePoint Pharmaceuticals, Inc.: SWOT Analysis
Figure 13.27: Gaplast GmbH: Overall Product Portfolio
Figure 13.28: Gaplast GmbH: SWOT Analysis
Figure 13.29: Gerresheimer AG: Overall Product Portfolio
Figure 13.30: Gerresheimer AG: Overall Financials, 2018-2020
Figure 13.31: Gerresheimer AG: Revenue (by Segment), 2018-2020
Figure 13.32: Gerresheimer AG: Revenue (by Region), 2018-2020
Figure 13.33: Gerresheimer AG: R&D Expense, 2018-2020
Figure 13.34: Gerresheimer AG: SWOT Analysis
Figure 13.35: Jotteq Inc.: Overall Product Portfolio
Figure 13.36: Jotteq Inc.: SWOT Analysis
Figure 13.37: Nemera: Overall Product Portfolio
Figure 13.38: Nemera: SWOT Analysis
Figure 13.39: Nipro Corporation: Overall Product Portfolio
Figure 13.40: Nipro Corporation: Overall Financials, 2018-2020
Figure 13.41: Nipro Corporation: Revenue (by Segment), 2018-2020
Figure 13.42: Nipro Corporation: Revenue (by Region), 2018-2020
Figure 13.43: Nipro Corporation: R&D Expense, 2018-2020
Figure 13.44: Nipro Corporation: SWOT Analysis
Figure 13.45: Ocular Therapeutix, Inc.: Overall Product Portfolio
Figure 13.46: Ocular Therapeutix, Inc.: Overall Financials, 2018-2020
Figure 13.47: Ocular Therapeutix, Inc.: R&D Expense, 2018-2020
Figure 13.48: Ocular Therapeutix, Inc.: SWOT Analysis
Figure 13.49: Owen Mumford: Overall Product Portfolio
Figure 13.50: Owen Mumford: SWOT Analysis
Figure 13.51: Silgan Holdings Inc.: Overall Product Portfolio
Figure 13.52: Silgan Holdings Inc.: Overall Financials, 2018-2020
Figure 13.53: Silgan Holdings Inc.: Revenue (by Segment), 2018-2020
Figure 13.54: Silgan Holdings Inc.: Revenue (by Region), 2018-2020
Figure 13.55: Silgan Holdings Inc.: SWOT Analysis
Figure 13.56: Terumo Corporation: Overall Product Portfolio
Figure 13.57: Terumo Corporation: Overall Financials, 2018-20